Completed NA INTERVENTIONAL 2-arm NCT00522743

Growth and Metabolic Response to GH and GnRHa Treatment Versus GH Alone in Boys Born SGA.

Two Arms, Open, Controlled, Prospective, Intervention Study to Evaluate the Growth and Metabolic Response to Growth Hormone and Gonadotropin-releasing Hormone Agonist Treatment Versus Growth Hormone Alone in Boys Born SGA

Sponsor: Pfizer

Conditions SGA and Growth

Interventions growth hormone growth hormone and gonadotropin-releasing hormone agonist

Updated 6 times since 2017 Last updated: Jul 13, 2010 Started: May 31, 2005 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00522743, this NA trial focuses on SGA and Growth and remains completed. Sponsored by Pfizer, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
Rabin Medical Center

Data source: Rabin Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Petah Tikva, Israel